Susan M. Chang

发表

Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.

Susan M. Chang, M. Gilbert, M. Mehta, 2020, Neuro-oncology.

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.

Timothy F Cloughesy, Mark R Gilbert, Patrick Y Wen, 2008, Neuro-oncology.

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.

Susan M. Chang, W. Yung, M. Prados, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.

Susan M. Chang, P. Brown, M. Mehta, 2013, The Lancet. Oncology.

Bromodeoxyuridine labeling index in glioblastoma multiforme: relation to radiation response, age, and survival.

M. Prados, M. McDermott, P. Gutin, 1996, International journal of radiation oncology, biology, physics.

It is time to include patients with brain tumors in phase I trials in oncology.

Susan M. Chang, W. Yung, M. Prados, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR overexpression and radiation response in glioblastoma multiforme.

M. Berger, K. Aldape, M. Prados, 2001, International journal of radiation oncology, biology, physics.

Radiation response and survival time in patients with glioblastoma multiforme.

M. Prados, M. McDermott, P. Gutin, 1996, Journal of neurosurgery.

Sarcomas subsequent to cranial irradiation.

M. Prados, D. Larson, A. Bollen, 1995, Neurosurgery.

DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.

Susan M. Chang, M. Berger, S. Vandenberg, 2011, Neuro-oncology.

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma

Susan M. Chang, K. Aldape, M. Prados, 2009, Journal of Neuro-Oncology.

Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.

M. Prados, J. Uhm, K. Hess, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs

Susan M. Chang, M. Prados, P. Wen, 2004, Investigational New Drugs.

A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.

M. Prados, M. Mehta, K. Fink, 2000, Neuro-oncology.

Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?

W. Yung, M. Prados, M. Gilbert, 2011, Neuro-oncology.

Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.

Susan M. Chang, W. Yung, M. Prados, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: results of a Phase II study.

M. Prados, K. Lamborn, W. Wara, 1999, International journal of radiation oncology, biology, physics.